Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Brain Neoplasms 2313Glioblastoma 2016Glioma 1402Central Nervous System Neoplasms 692Astrocytoma 668Neuroblastoma 647Gliosarcoma 480Oligodendroglioma 405Neoplasms 405Breast Neoplasms 327Medulloblastoma 307Carcinoma, Non-Small-Cell Lung 256Meningioma 229Recurrence 224Sarcoma 215Melanoma 207Neoplasm Metastasis 202Ependymoma 200Lung Neoplasms 199Neurofibromatosis 1 169Lymphoma 162Meningeal Carcinomatosis 138Osteosarcoma 135Ovarian Neoplasms 132Wilms Tumor 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 123Head and Neck Neoplasms 117Lymphoma, Non-Hodgkin 116Diffuse Intrinsic Pontine Glioma 113Rhabdomyosarcoma 107

Interventions

XENP 1595 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Tauopathies × CNS × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

NCT05321498 2023-09-28

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Inmune Bio, Inc.

Phase 2 Withdrawn
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Tauopathies, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon âš¡